{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:49:16Z","timestamp":1778888956041,"version":"3.51.4"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":409,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["55437631"],"award-info":[{"award-number":["55437631"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["55437631"],"award-info":[{"award-number":["55437631"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Cardiac amyloidosis (CA) is a potentially fatal multisystemic disease that remains significantly underdiagnosed, particularly in the Middle East. This study aims to evaluate the prevalence and clinical characteristics of CA in a high-risk population at a tertiary centre in Saudi Arabia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional, retrospective, single-centre study was conducted at a tertiary hospital in Riyadh, Saudi Arabia. We reviewed the medical records of heart failure patients seen between August 2018 and July 2022 who exhibited red flags for CA and subsequently underwent CA screening. Red flags that prompted the workup included at least two of the following factors: the presence of unilateral or bilateral carpal tunnel syndrome, a family history of transthyretin amyloid (ATTR) amyloidosis and specific electrocardiographic features (relative\/absolute low QRS voltage, pseudoinfarct pattern and atrioventricular\/interventricular conduction abnormalities). Echocardiographic red flags included mainly increased wall thickness (\u226512 mm), significant diastolic dysfunction, reduced left ventricular (LV) longitudinal function, right ventricular (RV) dysfunction and elevated right atrial (RA)\/pulmonary artery (PA) pressure. Cardiac magnetic resonance (CMR) red flags included aspects similar to those in an echocardiogram as well as a subendocardial or transmural late gadolinium enhancement (LGE) pattern. These patients were assessed for CA through technetium-99m pyrophosphate ([99mTc]Tc-PYP) bone scintigraphy, serum and urine protein electrophoresis with immunofixation and a serum-free light chain assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 177 patients were screened, of which 21.0 (11.9%) patients were diagnosed with transthyretin amyloid CA (ATTR-CA) and 13 (7.3%) patients were diagnosed with light chain CA (AL-CA). Compared with patients with negative\/equivocal [99mTc]Tc-PYP scans (grades 0\u20131), patients with positive [99mTc]Tc-PYP scans (grades 2\u20133) were older (78.0 vs. 68.0 years, P &amp;lt; 0.001), had higher levels of troponin (P = 0.003) and N-terminal pro-brain natriuretic peptide (NT-proBNP) (P &amp;lt; 0.001), had a higher LV mass index (P &amp;lt; 0.001), displayed a more depressed global longitudinal strain (GLS) (P &amp;lt; 0.001) with a greater prevalence of a relative apical sparing pattern (P &amp;lt; 0.001) and demonstrated a higher incidence of first-degree atrioventricular block (P = 0.008) and low voltage patterns on electrocardiography (P &amp;lt; 0.001). Patients with ATTR-CA and AL-CA were more likely to have a subendocardial or transmural LGE pattern on CMR (P &amp;lt; 0.001) and had a significantly lower overall survival (P &amp;lt; 0.001) when compared with other heart failure aetiologies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first study to describe the clinical characteristics and outcomes of CA in the Middle East and Saudi Arabia. The prevalence of CA among screened heart failure patients here aligns with major international studies, suggesting significant underdiagnosis in the region. Therefore, larger multicentric studies and regional screening programmes are urgently needed to accurately characterize the epidemiology and outcomes of CA in the Middle East.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15045","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T02:43:55Z","timestamp":1725245035000},"page":"4348-4359","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["First Report of the Clinical Characteristics and Outcomes of Cardiac Amyloidosis in Saudi Arabia"],"prefix":"10.1093","volume":"11","author":[{"given":"Omar","family":"Ahmad","sequence":"first","affiliation":[{"name":"College of Medicine, Al Faisal University , Riyadh ,","place":["Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed H.","family":"Omer","sequence":"additional","affiliation":[{"name":"School of Medicine, Cardiff University , Cardiff ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Janjua","sequence":"additional","affiliation":[{"name":"College of Medicine, Al Faisal University , Riyadh ,","place":["Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Islam","family":"Alayary","sequence":"additional","affiliation":[{"name":"Rare Diseases Medical Affairs, Pfizer Inc. , Jeddah ,","place":["Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Fathala","sequence":"additional","affiliation":[{"name":"Department of Radiology, King Faisal Specialist Hospital and Research Center , Riyadh ,","place":["Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani","family":"Alsergani","sequence":"additional","affiliation":[{"name":"College of Medicine, Al Faisal University , Riyadh ,","place":["Saudi Arabia"]},{"name":"Heart Center, King Faisal Specialist Hospital and Research Center , Riyadh ,","place":["Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bandar","family":"Alamro","sequence":"additional","affiliation":[{"name":"Heart Center, King Faisal Specialist Hospital and Research Center , Riyadh ,","place":["Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[{"name":"Department of Cardiology, French Referral Center for Cardiac Amyloidosis, Henri Mondor University Hospital, Assistance-Publique H\u00f4pitaux de Paris (APHP) , Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahaa","family":"Fadel","sequence":"additional","affiliation":[{"name":"College of Medicine, Al Faisal University , Riyadh ,","place":["Saudi Arabia"]},{"name":"Heart Center, King Faisal Specialist Hospital and Research Center , Riyadh ,","place":["Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dania","family":"Mohty","sequence":"additional","affiliation":[{"name":"College of Medicine, Al Faisal University , Riyadh ,","place":["Saudi Arabia"]},{"name":"Heart Center, King Faisal Specialist Hospital and Research Center , Riyadh ,","place":["Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,9,1]]},"reference":[{"key":"2026012113121926100_ehf215045-bib-0001","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/clc.23572","article-title":"Cardiac amyloidosis\u2014A review of current literature for the practicing physician","volume":"44","author":"Ash","year":"2021","journal-title":"Clin Cardiol"},{"key":"2026012113121926100_ehf215045-bib-0002","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/joim.13169","article-title":"Systemic amyloidosis from A (AA) to T (ATTR): A review","volume":"289","author":"Muchtar","year":"2021","journal-title":"J Intern Med"},{"key":"2026012113121926100_ehf215045-bib-0003","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012113121926100_ehf215045-bib-0004","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jacc.2017.11.037","article-title":"Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement","volume":"71","author":"Scully","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012113121926100_ehf215045-bib-0005","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00392-019-01490-2","article-title":"When and how do patients with cardiac amyloidosis die?","volume":"109","author":"Escher","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"2026012113121926100_ehf215045-bib-0006","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3390\/biomedicines10071566","article-title":"Re-definition of the epidemiology of cardiac amyloidosis","volume":"10","author":"Rossi","year":"2022","journal-title":"Biomedicine"},{"key":"2026012113121926100_ehf215045-bib-0007","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026012113121926100_ehf215045-bib-0008","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113121926100_ehf215045-bib-0009","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.jchf.2019.07.007","article-title":"A changing landscape of mortality for systemic light chain amyloidosis","volume":"7","author":"Barrett","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026012113121926100_ehf215045-bib-0010","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/13506129.2018.1498782","article-title":"Seven factors predict a delayed diagnosis of cardiac amyloidosis","volume":"25","author":"Bishop","year":"2018","journal-title":"Amyloid"},{"key":"2026012113121926100_ehf215045-bib-0011","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1265681","article-title":"Transthyretin cardiac amyloidosis in Saudi Arabia and the Middle East: Insights, projected prevalence and practical applications","volume":"10","author":"Mohty","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026012113121926100_ehf215045-bib-0012","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113121926100_ehf215045-bib-0013","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"2026012113121926100_ehf215045-bib-0014","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"key":"2026012113121926100_ehf215045-bib-0015","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jcmg.2020.08.035","article-title":"Left ventricular mass-to-strain ratio predicts cardiac amyloid subtype","volume":"14","author":"Geenty","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012113121926100_ehf215045-bib-0016","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.jcmg.2015.11.013","article-title":"The relation of ejection fraction and global longitudinal strain in amyloidosis: Implications for differential diagnosis","volume":"9","author":"Pagourelias","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012113121926100_ehf215045-bib-0017","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: Evolving diagnosis and management: A scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"2026012113121926100_ehf215045-bib-0018","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2\u2014Evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"2026012113121926100_ehf215045-bib-0019","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026012113121926100_ehf215045-bib-0020","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jclinepi.2022.08.016","article-title":"Handling missing data in clinical research","volume":"151","author":"Heymans","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"2026012113121926100_ehf215045-bib-0021","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"2026012113121926100_ehf215045-bib-0022","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: A report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Writing Committee","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026012113121926100_ehf215045-bib-0023","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026012113121926100_ehf215045-bib-0024","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1002\/ehf2.14364","article-title":"Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan","volume":"10","author":"Naito","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026012113121926100_ehf215045-bib-0025","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/clc.23985","article-title":"Cardiac amyloidosis: A survey of current awareness, diagnostic modalities, treatment practices, and clinical challenges among cardiologists in selected Middle Eastern countries","volume":"46","author":"Mohty","year":"2023","journal-title":"Clin Cardiol"},{"key":"2026012113121926100_ehf215045-bib-0026","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s10741-021-10164-z","article-title":"The genetics of cardiac amyloidosis","volume":"27","author":"Arno","year":"2022","journal-title":"Heart Fail Rev"},{"key":"2026012113121926100_ehf215045-bib-0027","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40246-021-00351-2","article-title":"Established and candidate transthyretin amyloidosis variants identified in the Saudi population by data mining","volume":"15","author":"Abouelhoda","year":"2021","journal-title":"Hum Genomics"},{"key":"2026012113121926100_ehf215045-bib-0028","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/ejhf.2769","article-title":"N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis","volume":"25","author":"Vergaro","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026012113121926100_ehf215045-bib-0029","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"key":"2026012113121926100_ehf215045-bib-0030","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026012113121926100_ehf215045-bib-0031","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.116.005588","article-title":"Echo parameters for differential diagnosis in cardiac amyloidosis: A head-to-head comparison of deformation and nondeformation parameters","volume":"10","author":"Pagourelias","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026012113121926100_ehf215045-bib-0032","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","article-title":"How to image cardiac amyloidosis: A practical approach","volume":"13","author":"Dorbala","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012113121926100_ehf215045-bib-0033","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"2026012113121926100_ehf215045-bib-0034","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1002\/ehf2.12986","article-title":"Heart failure from ATTRwt amyloid cardiomyopathy is associated with poor prognosis","volume":"7","author":"Kocher","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012113121926100_ehf215045-bib-0035","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/ehf2.14337","article-title":"Patients with cardiac amyloidosis are at a greater risk of mortality and hospital readmission after acute heart failure","volume":"10","author":"Berthelot","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026012113121926100_ehf215045-bib-0036","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/ehjqcco\/qcab031","article-title":"Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: An analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies","volume":"8","author":"Rozenbaum","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026012113121926100_ehf215045-bib-0037","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/6\/4348\/64516639\/eschf_11_6_4348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/6\/4348\/64516639\/eschf_11_6_4348.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:14:18Z","timestamp":1769019258000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/6\/4348\/8269376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,9,1]]},"published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15045","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,9,1]]},"assertion":[{"value":"2024-04-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}